Overall, CAR-T therapy for pancreatic cancer is progressing from preclinical exploration toward clinical translation, with a focus on representative tumor-associated targets, particularly MSLN and CLDN18.2, which show promising antitumor activity; however, durable clinical responses remain difficult to achieve.